Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment.

Objective: This study evaluated the pharmacokinetic (PK) characteristics of benapenem in subjects with mild to moderate renal impairment to provide a reference for benapenem dosing regimens in this patient population. Methods: Eighteen subjects were enrolled in this study. Each subject received a si...

Full description

Bibliographic Details
Published in:European Journal of Clinical Pharmacology Vol. 78; no. 7; pp. 1079 - 1087
Main Authors: Yang, Haijing, Zhang, Min, Chen, Yuancheng, Ren, Hong, Zhang, Hong, Yu, Chen, Lu, Jianda, You, Li, Yu, Jicheng, Liang, Hong, Xiao, Cuilan, He, Zishuang, Wu, Jufang, Xue, Jun, Zhang, Jing
Format: clinical trial research tables/charts Journal Article
Published: Springer Nature Jul2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157415227&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 157415227
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Jul2022
      vid: 78
      iid: 7
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        157415227
        156158987
        157415227
        157415227
        10.1007/s00228-022-03317-y
        157415227
      ppf: 1079
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment.
      aug:
        au:
          Yang, Haijing
          Zhang, Min
          Chen, Yuancheng
          Ren, Hong
          Zhang, Hong
          Yu, Chen
          Lu, Jianda
          You, Li
          Yu, Jicheng
          Liang, Hong
          Xiao, Cuilan
          He, Zishuang
          Wu, Jufang
          Xue, Jun
          Zhang, Jing
        affil: Phase I Unit, Huashan Hospital, Fudan University, No.12, Middle Wulumuqi Road, 200040, Shanghai, China
      sug:
        subj:
          Kidney Diseases Drug Therapy
          Antibiotics, Lactam Pharmacokinetics
          Antibiotics, Lactam Administration and Dosage
          Administration, Intravenous
          Severity of Illness
          Treatment Outcomes
          Human
          Patient Safety
          Adverse Drug Event
          Drug Monitoring
          Clinical Trials
      ab: Objective: This study evaluated the pharmacokinetic (PK) characteristics of benapenem in subjects with mild to moderate renal impairment to provide a reference for benapenem dosing regimens in this patient population. Methods: Eighteen subjects were enrolled in this study. Each subject received a single dose of benapenem intravenously (1.0 g in 100 ml of 0.9% saline) followed by blood and urine collection to measure the concentrations of benapenem and its major metabolite. PK analysis was performed to evaluate the effect of varying degrees of renal impairment on the PK characteristics of benapenem. The safety of benapenem was also evaluated. Results: In subjects with normal renal function, mild renal impairment, and moderate renal impairment, the maximum plasma benapenem concentrations were 163 ± 6.58 mg/L, 138 ± 17.4 mg/L, and 134 ± 0.11 mg/L, respectively (15.3% and 17.8% lower in subjects with mild and moderate renal impairment, respectively, than in subjects with normal renal function). The areas under the plasma concentration–time curve (AUC0-inf) were 1153.67 ± 143.2 mg·h/L, 1129.17 ± 241.41 mg·h/L, and 1316.46 ± 229.83 mg·h/L, respectively (P > 0.05); the cumulative urinary excretion rates at 72 h after dosing were 52.61 ± 8.58%, 39.42 ± 8.35%, and 29.84 ± 9.15%, respectively; and the metabolic ratio (AUC0-inf_KBP-3331/AUC0-inf_benapenem) were 3.96 ± 0.35%, 5.56 ± 0.82%, and 8.24 ± 0.85%, respectively. No drug-related adverse events (AEs), serious AEs, or AEs leading to withdrawal occurred in this study. Conclusion: No adjustment to benapenem dosing is needed in patients with mild to moderate renal impairment. Clinical trial registration: Drug clinical trial registration and information publicity platform: http://www.chinadrugtrials.org.cn/index.html. Registration number: CTR20190760.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N